Development of a Novel Acoustic Resuscitation Monitor

描述（由申请人提供）：目前几乎一半的创伤死亡率直接或间接归因于出血性休克，在美国每年造成超过50，000例死亡和数千亿美元的经济成本。Active Signal Technologies提议开发一种声学复苏监测仪（ARM），用于真实的实时无创评估全身灌注，最终目标是开发一种可以在现场连续监测休克和复苏的设备。由于没有这样的设备存在，目前的灌注测试有显着的滞后时间，ARM可以显着改善患者的结果和降低成本，无论是在医院（第一阶段）和现场（第二阶段）设置。ARM技术基于Active Signal的脑声学监测器（BAM），该监测器在500多名创伤和100名中风患者的脑灌注研究中得到了有效证明。在第I阶段，Active Signal与马里兰州大学休克创伤中心将对大约100名患者进行可行性测试，数据收集时间为5次。具体目标是确定ARM使用脉冲波形特征指示的血管收缩与当前临床指标测量的全身灌注之间的关系，并重新配置BAM以监测3个动脉树水平的血管收缩。

DESCRIPTION (provided by applicant): Currently almost half of all trauma mortality is directly or indirectly attributable to hemorrhagic shock, accounting for more than 50,000 deaths yearly in the U.S. and hundreds of billions of dollars in economic costs. Active Signal Technologies proposes to develop an Acoustic Resuscitation Monitor (ARM) for enabling non-invasive assessment of systemic perfusion in real time, with the ultimate goal of developing a device that can continuously monitor shock and resuscitation in the field. As no such device exists and current perfusion tests have significant lag time, ARM can significantly improve patient outcome and lower costs both for in-hospital (Phase I) and field (Phase II) settings. The ARM technology is based on Active Signal's Brain Acoustic Monitor (BAM) - demonstrated effectively in brain perfusion studies on more than 500 trauma and 100 stroke patients. In Phase I Active Signal with the University of Maryland Shock Trauma Center will conduct feasibility tests on approximately 100 patients with 5 data collection times. Specific aims are to determine the relationship between vasoconstriction as indicated by ARM using pulse-waveform characteristics and systemic perfusion measured by current clinical metrics, and to reconfigure the BAM to monitor vasoconstriction at 3 arterial tree levels.